Philips wins FDA clearance for new detector-based radiotherapy system

Philips (NYSE:PHG) announced today that the FDA granted 510(k) clearance for its new detector-based spectral computed tomography (CT) radiotherapy solution.

The company says its Spectral CT 7500 RT marks the next step in personalized cancer care. It integrates the unique tumor visualization and tissue characterization capabilities of spectral CT into cancer treatment and planning. With it, radiation oncologists can precisely target radiation therapy to the specific physiological characteristics of a patient’s tumor. This minimizes damage to healthy surrounding tissue and reduces potential unwanted side effects.

Spectral CT 7500 RT combines true conventional and spectral CT capabilities in a single scan to integrate into existing workflows. Philips said it’s the first radiation therapy CT scanner to offer respiratory-gated spectral imaging. This gives radiation oncologists all the benefits of 4D conventional CT, plus improved visualization and quantification, according to the company.

Philips says its innovation helps reduce the costs of additional scans while enhancing accuracy and enabling more effective treatment plans. The company says Spectral CT demonstrated the ability to reduce proton stopping-power ratio (SPR) error by more than 50% compared to conventional CT. This improves the accuracy of radiation treatment and spares healthy tissue.

Sign up for Blog Updates